ZYBERNO
Stock Report
Updated Aug 31, 2026

Nkarta, Inc. (NKTX)

Healthcare • NASDAQ

$2.76

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
Nkarta, Inc. (NKTX) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-39.6%)
Debt-to-Equity (Solvency Risk):GOOD (0.59x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-33.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Nkarta, Inc. (NKTX) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, NKTX generated -$88.41M in Owner Earnings. Capital was deployed as follows: $1.10M invested in capital expenditures. Reinvestment rate: 8.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.76
Market Cap:$205.61M

Valuation Multiples (2)

P/B Ratio:0.83x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$254.19M

Price Action & Momentum (3)

Momentum Percentile:87 / 100
% of 52-Week High:74.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-30.5%
Reinvestment Rate:8.1%
Fundamental Growth Rate (g):-2.7%

Margin Analysis (1)

Ebitda Margin:-1,751,646.4%

Yield Metrics (2)

Earnings Yield:-$68.70
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-133.8%
Latest Earnings Filed:2026-08-10
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:7.98x
Quick Ratio:7.98x
Cash Ratio:1.06x

Leverage Analysis (3)

Debt To Equity Ttm:0.59x
Debt-to-Equity Ratio:0.59x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:164,484,000.00
Cash And Cash Equivalents:24,958,000.00
Long Term Debt:$66.26M
Net Debt:$48.58M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$132.25M

Bottom Line Performance (3)

-$117.32M
Income Before Tax:$0.00
Ebitda Ttm:-122,651,000.00

Operating Expenses (5)

Operating Expenses:132,251,000.00
R And D Expense:99,513,000.00
Sga Expense:32,738,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:4,311,655.1%
Sga To Revenue Percentage:1,418,457.5%
Ebitda Margin:-1,751,646.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$337.65M
Current Assets:$188.05M
Ppe Net:56,768,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:89,907,000.00
Current Liabilities:23,561,000.00
Long Term Debt:$66.26M
Short Term Debt:$7.28M

Equity & Capital (3)

Equity:$247.74M
Retained Earnings:-$716.51M
Common Stock:7,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:12,462,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,865,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$87.29M-$88.39M

Investment Activities (2)

Investing Cash Flow:$15.92M
Capital Expenditures Ttm:1,103,000.00

Financing Activities (3)

Financing Cash Flow:$6.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:9,600,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.58
-$1.58
Earnings Per Share Ttm:-$1.57

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.19

Book Value & Capital (2)

Book Value Per Share:$3.33
Cash Per Share:0.34

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$88.41M

Damodaran Growth Analysis (2)

Reinvestment Rate:8.1%
Fundamental Growth Rate (g):-2.7%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-1.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:NKTX
Company Name:Nkarta, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:74.49M
Shares Outstanding Basic:74.49M
Shares Outstanding Diluted:74.49M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 10:32:04 UTC
Data Timestamp:2026-08-19T02:01:54.196911
Scroll to Top